In a recent briefing, CB Insights reported increased funding in the healthcare sector for the first half of 2019 with $26.9 billion invested in healthcare companies across 2,258 deals globally. While promising, funding for full year 2019 is not projected to surpass the $58.5 billion raised by healthcare companies in 2018. The number of late-stage financings has also increased, showing signs of a maturing industry. In the first half of 2019, late-stage financings by healthcare companies accounted for 20% of all deals globally.
Within the healthcare industry, digital health companies are raising more capital in the United States than elsewhere in the world, with four of these companies completing "mega-rounds" (financings of over $100 million) in the first half of 2019. Interestingly, none of these four digital health companies have a "unicorn" designation, given to companies valued at over $1 billion. Currently, there are 38 healthcare unicorns globally, valued at over $90.7 billion. The U.S. is home to 31 of these healthcare unicorns.
Clinical trials-focused tech companies have raised $391 million in capital across 23 deals in the first half of 2019. More companies focusing on clinical trial technology have emerged as the shortening of preclinical development days directly affects returns for investors.
Artificial Intelligence ("AI") in healthcare companies have raised over $1.4 billion across 153 deals in the first half of 2019. Patent applications for healthcare AI are up 5x over 2015, which may explain the increased interest and funding in companies in this sub-sector.
Mental health and wellness companies have set a quarterly record for funding, with 26 deals raising $321 million completed in the second quarter of 2019, bringing total funding to $523 million for 2019. As mental health has become a more widely talked about topic, demand for mental health and wellness services has surpassed supply by psychiatrists and other professionals, allowing for mental health and wellness apps and technology to fill these gaps.
For additional information and for CB Insight's commentary, see their Global Healthcare Report.
Visit us at mayerbrown.com
Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.
© Copyright 2019. The Mayer Brown Practices. All rights reserved.
This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.
